Literature DB >> 20094047

Targeting the cancer kinome through polypharmacology.

Zachary A Knight1, Henry Lin, Kevan M Shokat.   

Abstract

Kinase inhibitors are the largest class of new cancer drugs. However, it is already apparent that most tumours can escape from the inhibition of any single kinase. If it is necessary to inhibit multiple kinases, how do we choose which ones? In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20094047      PMCID： PMC2880454          DOI： 10.1038/nrc2787

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  94 in total

1.  Kinase requirements in human cells: II. Genetic interaction screens identify kinase requirements following HPV16 E7 expression in cancer cells.

Authors:  Amy Baldwin; Wenliang Li; Miranda Grace; Joseph Pearlberg; Ed Harlow; Karl Münger; Dorre A Grueneberg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-23       Impact factor: 11.205

2.  Erlotinib in previously treated non-small-cell lung cancer.

Authors:  Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

3.  BRAF mutation predicts sensitivity to MEK inhibition.

Authors:  David B Solit; Levi A Garraway; Christine A Pratilas; Ayana Sawai; Gad Getz; Andrea Basso; Qing Ye; Jose M Lobo; Yuhong She; Iman Osman; Todd R Golub; Judith Sebolt-Leopold; William R Sellers; Neal Rosen
Journal:  Nature       Date:  2005-11-06       Impact factor: 49.962

4.  The consensus coding sequences of human breast and colorectal cancers.

Authors:  Tobias Sjöblom; Siân Jones; Laura D Wood; D Williams Parsons; Jimmy Lin; Thomas D Barber; Diana Mandelker; Rebecca J Leary; Janine Ptak; Natalie Silliman; Steve Szabo; Phillip Buckhaults; Christopher Farrell; Paul Meeh; Sanford D Markowitz; Joseph Willis; Dawn Dawson; James K V Willson; Adi F Gazdar; James Hartigan; Leo Wu; Changsheng Liu; Giovanni Parmigiani; Ben Ho Park; Kurtis E Bachman; Nickolas Papadopoulos; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu
Journal:  Science       Date:  2006-09-07       Impact factor: 47.728

5.  Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.

Authors:  Ultan McDermott; Sreenath V Sharma; Lori Dowell; Patricia Greninger; Clara Montagut; Jennifer Lamb; Heidi Archibald; Raul Raudales; Angela Tam; Diana Lee; S Michael Rothenberg; Jeffrey G Supko; Raffaella Sordella; Lindsey E Ulkus; A John Iafrate; Shyamala Maheswaran; Ching Ni Njauw; Hensin Tsao; Lisa Drew; Jeff H Hanke; Xiao-Jun Ma; Mark G Erlander; Nathanael S Gray; Daniel A Haber; Jeffrey Settleman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-06       Impact factor: 11.205

6.  Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.

Authors:  Jolien Tol; Miriam Koopman; Annemieke Cats; Cees J Rodenburg; Geert J M Creemers; Jolanda G Schrama; Frans L G Erdkamp; Allert H Vos; Cees J van Groeningen; Harm A M Sinnige; Dirk J Richel; Emile E Voest; Jeroen R Dijkstra; Marianne E Vink-Börger; Ninja F Antonini; Linda Mol; Johan H J M van Krieken; Otilia Dalesio; Cornelis J A Punt
Journal:  N Engl J Med       Date:  2009-02-05       Impact factor: 91.245

7.  Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma.

Authors:  Etienne Meylan; Alison L Dooley; David M Feldser; Lynn Shen; Erin Turk; Chensi Ouyang; Tyler Jacks
Journal:  Nature       Date:  2009-10-21       Impact factor: 49.962

8.  MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.

Authors:  Francis J Giles; Jorge Cortes; Dan Jones; Donald Bergstrom; Hagop Kantarjian; Steven J Freedman
Journal:  Blood       Date:  2006-09-21       Impact factor: 22.113

9.  Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.

Authors:  Natalia V Sergina; Megan Rausch; Donghui Wang; Jimmy Blair; Byron Hann; Kevan M Shokat; Mark M Moasser
Journal:  Nature       Date:  2007-01-07       Impact factor: 49.962

10.  Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.

Authors:  Neil P Shah; Brian J Skaggs; Susan Branford; Timothy P Hughes; John M Nicoll; Ronald L Paquette; Charles L Sawyers
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808
View more
  257 in total

1.  A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis.

Authors:  Stefanie Galbán; April A Apfelbaum; Carlos Espinoza; Kevin Heist; Henry Haley; Karan Bedi; Mats Ljungman; Craig J Galbán; Gary D Luker; Marcian Van Dort; Brian D Ross
Journal:  Mol Cancer Ther       Date:  2017-08-03       Impact factor: 6.261

Review 2.  SCF ubiquitin ligase-targeted therapies.

Authors:  Jeffrey R Skaar; Julia K Pagan; Michele Pagano
Journal:  Nat Rev Drug Discov       Date:  2014-11-14       Impact factor: 84.694

3.  Comprehensive analysis of kinase inhibitor selectivity.

Authors:  Mindy I Davis; Jeremy P Hunt; Sanna Herrgard; Pietro Ciceri; Lisa M Wodicka; Gabriel Pallares; Michael Hocker; Daniel K Treiber; Patrick P Zarrinkar
Journal:  Nat Biotechnol       Date:  2011-10-30       Impact factor: 54.908

4.  Global molecular dysfunctions in gastric cancer revealed by an integrated analysis of the phosphoproteome and transcriptome.

Authors:  Tiannan Guo; Sze Sing Lee; Wai Har Ng; Yi Zhu; Chee Sian Gan; Jiang Zhu; Haixia Wang; Shiang Huang; Siu Kwan Sze; Oi Lian Kon
Journal:  Cell Mol Life Sci       Date:  2010-10-16       Impact factor: 9.261

5.  Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry.

Authors:  Holger Franken; Toby Mathieson; Dorothee Childs; Gavain M A Sweetman; Thilo Werner; Ina Tögel; Carola Doce; Stephan Gade; Marcus Bantscheff; Gerard Drewes; Friedrich B M Reinhard; Wolfgang Huber; Mikhail M Savitski
Journal:  Nat Protoc       Date:  2015-09-17       Impact factor: 13.491

6.  Computational Modeling of Kinase Inhibitor Selectivity.

Authors:  Govindan Subramanian; Manish Sud
Journal:  ACS Med Chem Lett       Date:  2010-07-28       Impact factor: 4.345

7.  How chemoproteomics can enable drug discovery and development.

Authors:  Raymond E Moellering; Benjamin F Cravatt
Journal:  Chem Biol       Date:  2012-01-27

8.  Phenotypic Screening Combined with Machine Learning for Efficient Identification of Breast Cancer-Selective Therapeutic Targets.

Authors:  Prson Gautam; Alok Jaiswal; Tero Aittokallio; Hassan Al-Ali; Krister Wennerberg
Journal:  Cell Chem Biol       Date:  2019-05-02       Impact factor: 8.116

9.  Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor.

Authors:  Marcian E Van Dort; Stefanie Galbán; Hanxiao Wang; Judith Sebolt-Leopold; Christopher Whitehead; Hao Hong; Alnawaz Rehemtulla; Brian D Ross
Journal:  Bioorg Med Chem       Date:  2015-03-06       Impact factor: 3.641

10.  Kinome-wide activity modeling from diverse public high-quality data sets.

Authors:  Stephan C Schürer; Steven M Muskal
Journal:  J Chem Inf Model       Date:  2013-01-09       Impact factor: 4.956
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.